JP2024527023A - His低応答者の治療 - Google Patents
His低応答者の治療 Download PDFInfo
- Publication number
- JP2024527023A JP2024527023A JP2024504808A JP2024504808A JP2024527023A JP 2024527023 A JP2024527023 A JP 2024527023A JP 2024504808 A JP2024504808 A JP 2024504808A JP 2024504808 A JP2024504808 A JP 2024504808A JP 2024527023 A JP2024527023 A JP 2024527023A
- Authority
- JP
- Japan
- Prior art keywords
- therapy
- obiscetrapib
- ldl
- subject
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21187721 | 2021-07-26 | ||
| EP21187721.2 | 2021-07-26 | ||
| PCT/EP2022/070780 WO2023006657A1 (en) | 2021-07-26 | 2022-07-25 | Treatment of his hyporesponders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527023A true JP2024527023A (ja) | 2024-07-19 |
| JP2024527023A5 JP2024527023A5 (cg-RX-API-DMAC7.html) | 2025-07-03 |
Family
ID=77358089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504808A Pending JP2024527023A (ja) | 2021-07-26 | 2022-07-25 | His低応答者の治療 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230041138A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4376832B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527023A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240040767A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117940125A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022320869A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3227153A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4376832T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3071242T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4376832T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310115A (cg-RX-API-DMAC7.html) |
| LT (1) | LT4376832T (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024001170A (cg-RX-API-DMAC7.html) |
| PL (1) | PL4376832T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT4376832T (cg-RX-API-DMAC7.html) |
| TW (1) | TWI922719B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023006657A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12006305B2 (en) | 2022-07-05 | 2024-06-11 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| WO2025146415A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Improvement in atherosclerotic plaque characteristics with obicetrapib |
| EP4746866A1 (en) * | 2024-09-17 | 2026-05-27 | NewAmsterdam Pharma B.V. | Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd) |
| WO2026146129A1 (en) * | 2025-01-02 | 2026-07-09 | Newamsterdam Pharma B.V. | Magnesium salts of obicetrapib |
| WO2026146132A1 (en) * | 2025-01-02 | 2026-07-09 | Newamsterdam Pharma B.V. | Salts of obicetrapib |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017525729A (ja) * | 2014-08-28 | 2017-09-07 | デジマ・ファルマ・ベー・フェー | コレステリルエステル転送タンパク質阻害剤及びHMG CoA還元酵素阻害剤を含む医薬組成物及び治療併用剤 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| KR20150028233A (ko) | 2012-05-07 | 2015-03-13 | 옴테라 파마슈티칼스, 인크. | 스타틴 및 오메가-3 지방산의 조성물 |
| CN107108558B (zh) | 2014-08-12 | 2019-11-19 | 狄智玛制药私人有限公司 | 制备用于制备四氢喹啉衍生物的合成中间体的方法 |
-
2022
- 2022-07-25 IL IL310115A patent/IL310115A/en unknown
- 2022-07-25 FI FIEP22754412.9T patent/FI4376832T3/fi active
- 2022-07-25 CN CN202280057367.XA patent/CN117940125A/zh active Pending
- 2022-07-25 KR KR1020247005859A patent/KR20240040767A/ko active Pending
- 2022-07-25 JP JP2024504808A patent/JP2024527023A/ja active Pending
- 2022-07-25 ES ES22754412T patent/ES3071242T3/es active Active
- 2022-07-25 MX MX2024001170A patent/MX2024001170A/es unknown
- 2022-07-25 CA CA3227153A patent/CA3227153A1/en active Pending
- 2022-07-25 TW TW111127830A patent/TWI922719B/zh active
- 2022-07-25 DK DK22754412.9T patent/DK4376832T3/da active
- 2022-07-25 LT LTEPPCT/EP2022/070780T patent/LT4376832T/lt unknown
- 2022-07-25 US US17/873,009 patent/US20230041138A1/en active Pending
- 2022-07-25 PL PL22754412.9T patent/PL4376832T3/pl unknown
- 2022-07-25 EP EP22754412.9A patent/EP4376832B1/en active Active
- 2022-07-25 AU AU2022320869A patent/AU2022320869A1/en active Pending
- 2022-07-25 EP EP26160076.1A patent/EP4789665A1/en active Pending
- 2022-07-25 PT PT227544129T patent/PT4376832T/pt unknown
- 2022-07-25 WO PCT/EP2022/070780 patent/WO2023006657A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017525729A (ja) * | 2014-08-28 | 2017-09-07 | デジマ・ファルマ・ベー・フェー | コレステリルエステル転送タンパク質阻害剤及びHMG CoA還元酵素阻害剤を含む医薬組成物及び治療併用剤 |
Non-Patent Citations (4)
| Title |
|---|
| G K HOVINGH ET AL.: "Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP)", LANCET, vol. 386, JPN6026024651, 2015, pages 452 - 460, ISSN: 0005885997 * |
| J P KASTELEIN ET AL.: "Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia", LANCET, vol. 385, JPN6026024654, 2015, pages 2153 - 2161, ISSN: 0005886000 * |
| NEWAMSTERDAM PHARMA (SPONSOR): "ClinicalTrials.gov ID NCT04753606: Randomized Study of Obicetrapib as an Adjunct to Statin Therapy (", CLINICALTRIALS.GOV, vol. 2021-07-08, JPN6026024653, July 2021 (2021-07-01), pages 1, ISSN: 0005885999 * |
| S RASHID: "Lower LDL is better ? can this be achieved withCETP inhibition therapy?", EXPERT REVIEW OF CARDIOVASCULAR THERAPY, vol. 18, no. 1, JPN6026024652, 2020, pages 1 - 5, ISSN: 0005885998 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3227153A1 (en) | 2023-02-02 |
| AU2022320869A1 (en) | 2024-02-01 |
| TW202310842A (zh) | 2023-03-16 |
| CN117940125A (zh) | 2024-04-26 |
| US20230041138A1 (en) | 2023-02-09 |
| DK4376832T3 (da) | 2026-06-15 |
| WO2023006657A1 (en) | 2023-02-02 |
| PT4376832T (pt) | 2026-06-11 |
| EP4789665A1 (en) | 2026-08-12 |
| PL4376832T3 (pl) | 2026-08-10 |
| TWI922719B (zh) | 2026-04-21 |
| IL310115A (en) | 2024-03-01 |
| LT4376832T (lt) | 2026-07-10 |
| KR20240040767A (ko) | 2024-03-28 |
| ES3071242T3 (en) | 2026-06-22 |
| MX2024001170A (es) | 2024-05-14 |
| FI4376832T3 (fi) | 2026-06-10 |
| EP4376832A1 (en) | 2024-06-05 |
| EP4376832B1 (en) | 2026-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7481071B2 (ja) | 対象の心血管イベントのリスクを低減する方法 | |
| EP4376832B1 (en) | Obicetrapib for use in treating of cardiovascular disease (cvd) in his hyporesponders | |
| JP6419927B2 (ja) | 対象の高感度(hs−crp)のレベルを低下させる組成物および方法 | |
| JP6196225B2 (ja) | 糖尿病新規発症低減用組成物 | |
| US9849104B2 (en) | Treatment of NASH with gemcabene | |
| JP5809115B2 (ja) | 心血管イベント予防用製剤 | |
| Stein et al. | Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins | |
| JP7862336B2 (ja) | 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのetc1002及び1種以上のスタチンを含む固定用量組合せ物 | |
| JPH07206712A (ja) | HMGCoAレダクターゼインヒビターを用いる心臓血管の疾患の発生の危険を予防または減少する方法 | |
| CN105473144A (zh) | 用于加速斑块消退的组合物和治疗方法 | |
| KR20230159380A (ko) | 고지혈증 또는 혼합형 이상지혈증을 앓고 있는 스타틴불내성 환자에서 사용하기 위한 오비세트라피브 및 에제티미브의 조합 요법 | |
| US9974767B2 (en) | Statins in the treatment of muscular dystrophies and myopathies | |
| JP2023181451A (ja) | 高トリグリセライド血症の治療方法 | |
| TWI741379B (zh) | 藥物組成物與包含膽固醇酯轉移蛋白抑制劑和HMG CoA還原酶抑制劑的治療組合 | |
| JP6207560B2 (ja) | 膵炎を治療するためのゲムカベンおよび誘導体 | |
| JP7356968B2 (ja) | 心血管疾患に有用な医薬 | |
| JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
| CN1437484A (zh) | 含有β-受体阻滞剂和任选的降胆固醇剂的新型制剂 | |
| BALLANTYNE | Lipid-Modifying Drugs | |
| WO2026062050A1 (en) | Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd) | |
| Young | Metabolic Regulation of Endothelial Dysfunction and Cardiovascular Risk | |
| HK1256960A1 (en) | Treatment of mixed dyslipidemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240326 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250625 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250625 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260616 |